At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Guanfacine +1 moredrug
Likely dose
Guanfacine 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Trial of Guanfacine, an Alpha 2 Adrenergic Agonist, for Spatial Neglect and Impaired Vigilance Following Stroke and Focal Brain Damage
In Brief
A Phase 2 clinical trial evaluating Guanfacine and Placebo for Stroke and Hemispatial Neglect. Completed, enrolled 13 participants across 1 site.
Detailed Summary
To find out if spatial neglect following stroke and brain injury can be reduced using guanfacine, a drug that was shown to improve neglect in two stroke patients in a previous pilot study (Malhotra et al, 2006). In this trial, the effects of guanfacine will be examined in a larger number of patients, and there will also be a systematic assessment of whether the drug is only effective in patients with particular patterns of brain damage.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStroke, Hemispatial Neglect
CountriesUnited Kingdom
CollaboratorsWellcome Trust
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2009
Enrollment StartApr 2010
Primary CompletionMar 2014
TodayJul 2026
First PostedAug 10, 2009
Enrollment StartApr 1, 2010
Primary CompletionMar 28, 2014
TodayJul 2, 2026
Enrollment to primary: 4.0 yearsPosted 16.9 years ago
Interventions
Guanfacinedrug
2mg oral guanfacine (encapsulated)
Placebodrug
placebo